Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 6, 2007, Pages 740-749

  Beier, Jutta ^a   Chanez, Pascal ^b   Martinot, Jean Benoit ^c   Schreurs, A J M ^d   Tkáčová, Ružena ^e   Bao, Weibin ^f   Jack, Damon ^g   Higgins, Mark ^g  

^a Institut fur Atemwegsforschung INSAF   (Germany)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e FACULTY HOSPITAL   (Slovakia)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

2 agonist; Bronchodilation; Indacaterol; Safety; Tolerability

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOSE; INDACATEROL; PLACEBO; POTASSIUM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART RATE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFESTATION; INNER EAR DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; POWDER INHALER; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINGLE DRUG DOSE; SKIN DISEASE; SPIROMETRY; STATISTICAL SIGNIFICANCE; THORAX DISEASE; TREATMENT DURATION; URINARY DYSFUNCTION; VASCULAR DISEASE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; INDANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POTASSIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 34548860934     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.09.001     Document Type: Article

References (23)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethseda: National Heart, Lung, and Blood Institute; April 2001: Updated 2005. GOLD website 〈www.goldcopd.com〉.
2. Schaanning J., Vilsvik J., Henriksen A.H., and Bratten G. Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 76 (1996) 57-60
3. Brogden R.N., and Faulds D. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 42 (1991) 895-912
4. Wallin A., Sandstrom T., Rosenhall L., and Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 48 (1993) 611-614
5. Quebe-Fehling E., Brambilla R., Bromly C.L., Fishwick K., Walters E.H., and Hendrick D.J. The duration of action of inhaled formoterol dry powder. Br J Clin Pract 50 (1996) 446-449
6. Sykes A.P., and Ayres J.G. A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma. Respir Med 84 (1990) 135-138
7. Bartow R.A., and Brogden R.N. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 55 (1998) 303-322
8. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
9. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San Pedro G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
10. Battram C., Charlton S.J., Cuenoud B., Dowling M.R., Fairhurst R.A., Farr D., et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317 (2006) 762-770
11. 2-agonist with 24-hour bronchodilation. Eur Respir J 26 Suppl 49 (2005) 253s, P1725
12. 2-agonist, in patients with stable asthma. Eur Respir J 26 Suppl 49 (2005) 253s, P1728
13. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethseda: National Heart, Lung, and Blood Institute. April 2001:GOLD website 〈www.goldcopd.com〉.
14. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Reslin R., and Yernault. Lung volumes and forced ventilatory flows. Eur Respir J 6 Suppl 16 (1993) 5-40
15. 2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study. Eur Respir J 26 Suppl 49 (2005) 253s, P1729
16. Venables T.L., Addlestone M.B., Smithers A.J., Blagden M.D., Weston D., Gooding T., et al. A comparison of the efficacy and patient acceptability of once daily budesonide via turbohaler and twice daily fluticasone propionate via disc-inhaler at an equal daily dose of 400 μg in adult asthmatics. Br J Clin Res 7 (1996) 15-32
17. Bennett J.A., Smyth E.T., Pavord I.D., Wilding P.J., and Tattersfield A.E. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 49 (1994) 771-774
18. Bennett J.A., and Tattersfield A.E. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 52 (1997) 458-464
19. Maconochie J.G., and Forster J.K. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol 33 (1992) 342-345
20. Bremner P., Woodman K., Burgess C., Crane J., Purdie G., Pearce N., et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 6 (1993) 204-210
21. Burgess C., Ayson M., Rajasingham S., Crane J., Della C.G., and Till M.D. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 54 (1998) 141-147
22. Maesen F.P., Costongs R., Smeets J.J., Brombacher P.J., and Zweers P.G. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 99 (1991) 1367-1373
23. Totterman K.J., Huhti L., Sutinen E., Backman R., Pietinalho A., Falck M., et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 12 (1998) 573-579